<DOC>
	<DOCNO>NCT00861068</DOCNO>
	<brief_summary>The objective trial investigate analgesic efficacy SPM 927 subject moderate severe neuropathic pain due Postherpetic Neuralgia ( PHN )</brief_summary>
	<brief_title>A Multi-Centre , Randomized , Double-Blind , Placebo Controlled Pilot Trial Assess Efficacy , Safety , Tolerability SPM 927 Subjects With Postherpetic Neuralgia ( PHN ) .</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<criteria>Subject clinically diagnose painful postherpetic neuralgia present least six month heal herpes zoster skin rash least one form allodynia Subject must least moderate pain ( mean pain intensity ≥ 4 10 baseline week Likert scale ) . Subject condition cause pain least severe postherpetic neuralgia . Subject surgical treatment neurolytic injection PHN Subject clinically significant ECG laboratory abnormality . Subject receive treatment antiepileptic drug ( AEDs ) , muscle relaxant , mexiletine , topical analgesic , antidepressant , opioids , nonsteroidal antiinflammatory drug ( NSAIDs ) , paracetamol , benzodiazepine , antiviral agent . Subject liver function test ( AST , ALT , alkaline phosphatase , total bilirubin GGT reference range ) &gt; 1,5 x ULN ( upper limit normal ) visit 1 Subject serum creatinine ≥ 2 time upper limit reference range Visit 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Lacosamide , Vimpat®</keyword>
</DOC>